Lupin Ltd’s biosimilar Ranibizumab has been launched by its commercial partner Sandoz across Europe, except Germany.
The launch follows the European Commission’s approval of Ranluspec in vial and pre-filled syringe presentations and marks a milestone in expanding access to quality biologic treatment options for retinal diseases, Lupin said.
Ranibizumab is used to treat patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization. It is “a recombinant humanised IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A,” the company said.
Thierry Volle, Lupin President EMEA and Emerging Markets, said the launch of Ranluspec in Europe with Sandoz expanded the biosimilar’s access to more patients suffering from retinal and choroidal vascular diseases.
Published on November 12, 2026
